| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30082367 | HIV | ENSG00000165025.15 | protein_coding | SYK | Yes | No | 6850 | P43405 |
| TVIS30083917 | HIV | ENSG00000165025.15 | protein_coding | SYK | Yes | No | 6850 | P43405 |
| TVIS30088546 | HIV | ENSG00000165025.15 | protein_coding | SYK | Yes | No | 6850 | P43405 |
| TVIS20028144 | HPV | ENSG00000165025.15 | protein_coding | SYK | Yes | No | 6850 | P43405 |
| TVIS20069786 | HPV | ENSG00000165025.15 | protein_coding | SYK | Yes | No | 6850 | P43405 |
| TVIS20063474 | HPV | ENSG00000165025.15 | protein_coding | SYK | Yes | No | 6850 | P43405 |
| TVIS20063725 | HPV | ENSG00000165025.15 | protein_coding | SYK | Yes | No | 6850 | P43405 |
| TVIS20064042 | HPV | ENSG00000165025.15 | protein_coding | SYK | Yes | No | 6850 | P43405 |
| TVIS20063675 | HPV | ENSG00000165025.15 | protein_coding | SYK | Yes | No | 6850 | P43405 |
| TVIS44026298 | HTLV-1 | ENSG00000165025.15 | protein_coding | SYK | Yes | No | 6850 | P43405 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SYK |
|---|---|
| DrugBank ID | DB12010 |
| Drug Name | Fostamatinib |
| Target ID | BE0001316 |
| UniProt ID | P43405 |
| Regulation Type | inhibitor |
| PubMed IDs | 26516587; 16946104; 33689480 |
| Citations | Rolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.@@Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES: R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. doi: 10.1124/jpet.106.109058. Epub 2006 Aug 31.@@Zheng TJ, Lofurno ER, Melrose AR, Lakshmanan HHS, Pang J, Phillips KG, Fallon ME, Kohs TCL, Ngo ATP, Shatzel JJ, Hinds MT, McCarty OJT, Aslan JE: Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. Am J Physiol Cell Physiol. 2021 May 1;320(5):C902-C915. doi: 10.1152/ajpcell.00296.2020. Epub 2021 Mar 10. |
| Groups | Approved; Investigational |
| Direct Classification | Methoxyanilines |
| SMILES | COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL2103830 |
